- Company Selects Gilead Sciences as its Exclusive Hepatitis C Treatment
- Program Offered Exclusively Through Company's Specialty Pharmacy,
SCHAUMBURG, IL, Feb. 3, 2015 /PRNewswire/ - Catamaran Corp. (NASDAQ: CTRX, TSX:
CCT), a leading provider of pharmacy benefit management (PBM) services
and technology, today announced that it is introducing a new clinical
outcomes-based program for hepatitis C treatment through its specialty
This new program will provide clients of Catamaran and BriovaRx an
innovative new approach to hepatitis C treatment. Centered on producing
positive health outcomes, the program will allow for overall treatment
costs to take into account clinical results. Patients will be monitored
during their entire treatment regimen through their participation in
BriovaRx's Hepatitis C Patient Management Program in order to support
"When looking for a hepatitis C partner, our goal was not only to ensure
the best possible value for the treatment cost alone, but also to
promote the best possible health outcomes for our patients," said
Albert Thigpen, SVP, Industry Relations & Supply Chain Management,
Catamaran. "This innovative strategy supports Catamaran's view that a
smarter approach to medicine has the power to lower overall healthcare
costs and promotes optimal outcomes over the long-term."
Gilead Sciences, Inc.'s hepatitis C treatments, Harvoni and Sovaldi, are the exclusive options on Catamaran's National and Value Formularies.
Catamaran's commercial clients will be eligible to participate in this
clinical outcomes-based program for hepatitis C if they utilize one of
these formularies or have a custom formulary and opt-in to the program.
"Catamaran and BriovaRx are rooted in delivering a more integrated
healthcare experience for patients through a holistic and personalized
approach," said, Sumit Dutta, M.D., M.B.A., Senior Vice President and
Chief Medical Officer, Catamaran. "Our clinical outcomes-based program
for hepatitis C supports this mission, empowering our nurses and
pharmacists to partner with patients in a way that truly drives better
health outcomes and ensures these high-cost therapies accomplish what
they were designed to do."
To offer patients personalized care and achieve higher persistency and
adherence rates, BriovaRx employs a variety of programs to aid
patients. BriovaRx's Hepatitis C Patient Management Program features a
nursing team that creates an individualized care plan for each patient
based on the complexity of their condition and co-morbidities.
Offerings like this have helped increase adherence and persistency for
patients, contributing to overall cost savings and improved clinical
Catamaran, the industry's fastest-growing pharmacy benefits manager,
helps organizations and the communities they serve take control of
prescription drug costs. Managing more than 350 million prescriptions
each year on behalf of over 32 million members, our flexible, holistic
solutions improve patient care and empower individuals to take charge
of their health. Processing one in every five prescription claims in
the U.S., Catamaran's skill and scale deliver compelling financial
results and sustainable improvement in the overall health of members.
Catamaran is headquartered in Schaumburg, Ill.
, with multiple locations
in the U.S. and Canada
. For more information, please visit CatamaranRx.com
, and for industry news and information, follow Catamaran on Twitter, @CatamaranCorp
Press Release Source: http://www.prnewswire.com/news-releases/catamaran-introducing-innovative-clinical-outcomes-based-program-for-hepatitis-c-treatment-290667831.html
Labels: BriovaRX, Catamaran, Exclusivity Deals, Gilead